查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018475

顱內動脈瘤市場：2026年至2032年全球市場預測（依治療方法、動脈瘤位置、患者年齡層及最終用戶分類）

Intracranial Aneurysm Market by Treatment Type, Aneurysm Location, Patient Age Group, End Users - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，顱內動脈瘤市值將達到 19.7 億美元，到 2026 年將成長至 24.2 億美元，到 2032 年將達到 83.8 億美元，年複合成長率為 22.95%。

主要市場統計數據
基準年 2025 19.7億美元
預計年份：2026年 24.2億美元
預測年份 2032 83.8億美元
複合年成長率 (%) 22.95%

這篇全面的概述介紹了顱內動脈瘤的臨床複雜性、診斷技術的進步以及正在重塑顱內動脈瘤治療的多學科護理路徑。

顱內動脈瘤的治療涉及神經外科、血管內治療、先進影像技術以及不斷發展的手術全期護理模式等許多複雜領域。過去十年間，臨床醫師和醫療設備研發人員在保留傳統外科手術技術以應對解剖結構複雜的病變的同時，也逐漸轉向微創治療方法。這種融合得益於醫療設備設計和影像解析度的不斷提升，從而提高了手術的精準度和病患選擇的準確性。

設備、影像技術和手術策略的快速發展，正在推動精準醫療的新時代，並帶來顱內動脈瘤治療的系統性變革。

目前，腦動脈瘤的治療正經歷變革性的轉變，這體現在醫療設備創新、先進診斷技術和手術策略等。醫療設備創新持續強調低輪廓、軟性結構，以改善輸送和血管癒合，同時適應複雜的神經血管解剖結構。血流控制和栓塞技術的進步改變了治療流程，使臨床醫生能夠治療以往被認為需要開放性手術的高風險解剖結構。

評估 2025 年美國關稅調整如何重組腦動脈瘤治療的供應鏈、採購慣例和臨床交付途徑。

2025年實施的關稅措施為顱內動脈瘤治療供應鏈帶來了複雜且多層次的貿易政策考量。依賴跨境採購植入、特殊金屬和前置作業時間零件的製造商正面臨原物料成本上漲和交貨週期延長的雙重挑戰。為此，許多供應商正在重新審視其採購策略，優先考慮供應商和合約的多元化，以減少對單一來源的依賴。

針對特定細分市場的見解，解釋治療方法、動脈瘤位置、患者人口統計特徵和臨床環境如何影響臨床路徑和實施趨勢。

分段分析顯示，不同治療方法、解剖部位、患者族群和醫療環境會導致不同的引入模式和臨床考慮。以治療方法類型（血管內彈簧圈栓塞術、血流導引裝置、外科夾閉術）分析，可以發現每種治療方法的獨特優勢。彈簧圈栓塞術仍是經血管內入路治療方法囊狀病灶的首選方法。血流導引裝置為需要血管重組的寬頸和梭形動脈瘤提供了更多選擇。外科夾閉術在複雜的血管分叉解剖結構和需要即時機械閉塞的破裂病變中仍然發揮著至關重要的作用。

從區域觀點看美洲、歐洲、中東和非洲以及亞太地區腦動脈瘤治療的臨床引入、基礎設施投資和進入途徑。

臨床實務、法律規範和醫療基礎設施的區域差異導致各大地區腦動脈瘤的治療方法各不相同。在美洲，專科中心的集中、整合式診療路徑以及日益注重手術療效的報銷模式，促進了先進血管內介入及相關技術的快速普及。該地區的臨床網路和轉診模式通常允許將高度複雜的病例集中在三級醫療機構，同時允許對合適的特定病例進行門診手術。

企業級分析：重點介紹成熟製造商、專業創新者和服務夥伴關係如何重塑其設備組合和臨床部署軌跡。

在企業層面，發展趨勢反映出成熟製造商、靈活敏捷的專業公司和新興參與企業共同推動創新設備平台和數位輔助工具的形成。成熟的醫療設備製造商繼續利用全球分銷管道、監管經驗和豐富的臨床證據，支持關鍵技術的廣泛臨床應用。同時，專業公司和Start-Ups則專注於差異化的技術優勢，例如新型血流控制架構、促進內皮化的生物活性塗層以及優先考慮在彎曲解剖結構內操控性的新一代遞送系統。

為醫療設備開發商、醫療保健提供者和保險公司提供切實可行的策略建議，以加速創新應用、增強韌性並改善以患者為中心的動脈瘤護理。

產業領導者應優先採取一系列策略行動，在應對營運和政策限制的同時，充分利用臨床創新。首先，將產品開發與臨床醫生檢驗的用例和真實世界數據（REW）項目相結合，可以減少部署阻力，並為採購委員會創造引人注目的價值提案。與高發臨床中心密切合作，並實施研究者主導的研究、註冊登記和培訓項目，可以建立持久的信譽，並加速最佳實踐的推廣。

本報告說明了一種高度透明的調查方法，該方法採用對臨床、商業和供應鏈數據的綜合分析來驗證檢驗並支持策略建議。

本研究採用多模態調查方法，綜合分析了顱內動脈瘤治療的發展趨勢，該方法整合了臨床文獻綜述、專家訪談、醫療設備附加檔和監管文件以及供應鏈分析。關鍵的定性資料包括對介入性神經放射科醫生、神經外科醫生、採購經理和醫療設備設計工程師的結構化訪談，揭示了實際臨床應用中的限制因素、技術性能考量以及推動技術應用的因素。這些觀點與同行評審的臨床研究、操作指南和已發布的監管文件進行交叉比對，以確保技術的準確性和臨床相關性。

簡明扼要的結論整合了臨床進展、系統性挑戰和策略重點，供致力於改善動脈瘤治療效果和獲取途徑的相關人員參考。

本分析整合了臨床創新、供應鏈演變和策略影響，從而對顱內動脈瘤治療的當前趨勢進行了全面的闡述。器械技術和影像技術的進步顯著拓展了治療選擇，而採購壓力和貿易政策變化等系統性因素則帶來了新的營運考量，影響著治療方案的部署和普及。這些趨勢的交匯凸顯了將臨床證據的產生與穩健的商業策略和針對性臨床醫生支持相結合的重要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：顱內動脈瘤市場（依治療方法分類）

  • 血管內彈簧圈栓塞術
  • 流染版
  • 手術夾

第9章：依動脈瘤位置分類的顱內動脈瘤市場

  • 前交通動脈
  • 基底動脈
  • 大腦中動脈
  • 後交通動脈

第10章：依患者年齡層分類的顱內動脈瘤市場

  • 成人版
  • 老年人
  • 兒童

第11章 顱內動脈瘤市場：依最終用戶分類

  • 門診手術中心
  • 診斷中心
  • 醫院

第12章 顱內動脈瘤市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 顱內動脈瘤市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 顱內動脈瘤市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國顱內動脈瘤市場

第16章：中國顱內動脈瘤市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Acandis GmbH
  • B. Braun Melsungen AG
  • Boston Scientific Corporation
  • Cook Group Inc
  • Delta Surgical
  • Evasc Neurovascular Enterprises ULC
  • InspireMD Inc
  • Integer Holdings Corporation
  • Integra LifeSciences
  • Johnson & Johnson
  • Kaneka Corporation
  • Medtronic plc
  • Merit Medical Systems Inc
  • MicroPort Scientific Corporation
  • Penumbra Inc
  • Phenox GmbH
  • Rapid Medical
  • Raumedic AG
  • Shape Memory Medical
  • Stryker Corporation
  • Terumo Corporation
  • Wallaby Medical
Product Code: MRR-A339DAEF9EC7

The Intracranial Aneurysm Market was valued at USD 1.97 billion in 2025 and is projected to grow to USD 2.42 billion in 2026, with a CAGR of 22.95%, reaching USD 8.38 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.97 billion
Estimated Year [2026] USD 2.42 billion
Forecast Year [2032] USD 8.38 billion
CAGR (%) 22.95%

A comprehensive introduction framing clinical complexity, diagnostic advances, and multidisciplinary care pathways reshaping intracranial aneurysm management

Intracranial aneurysm management occupies a complex intersection of neurosurgery, endovascular therapy, advanced imaging, and evolving perioperative care models. Over the past decade clinicians and device developers have shifted toward minimally invasive approaches while preserving surgical techniques for anatomically challenging lesions. This convergence has been driven by continuous improvements in device design and imaging resolution, which together improve procedural precision and patient selection.

Contemporary clinical pathways emphasize early detection, risk stratification, and interdisciplinary care planning that integrates neurocritical care, interventional neuroradiology, and neurosurgery. Diagnostic advances such as high-resolution vascular imaging and computational assessments of hemodynamic stress have enhanced clinicians' ability to characterize lesion morphology and rupture risk. Meanwhile, procedural refinements and enhanced perioperative protocols have reduced length of stay and perioperative morbidity, supporting broader adoption of ambulatory and hybrid care models.

Despite technological progress, barriers remain. Anatomical complexity, patient comorbidities, and variability of institutional expertise continue to shape treatment decisions. Reimbursement dynamics, supply chain pressures, and regulatory pathways also influence adoption timelines for novel devices. Consequently, strategic stakeholders must reconcile clinical evidence, operational capacity, and procurement realities to optimize care delivery for patients with intracranial aneurysms.

Rapid advancements in devices, imaging, and procedural strategies are catalyzing a new era of precision care and system-level change for intracranial aneurysm treatment

The landscape of intracranial aneurysm care is experiencing transformative shifts that span device innovation, diagnostic sophistication, and procedural strategy. Device innovation continues to favor low-profile, flexible constructs that accommodate tortuous neurovascular anatomy while improving deliverability and vessel healing. Flow modulation technologies and refinements in coil technology have altered therapeutic algorithms, enabling clinicians to treat anatomies that were once considered high risk for open surgery.

Diagnostics have kept pace through enhanced imaging modalities and the integration of computational tools that quantify aneurysm wall stress and flow patterns. These diagnostic improvements enable more granular risk stratification, guiding the timing and modality of intervention. Procedurally, there is growing adoption of hybrid approaches that combine endovascular and microsurgical techniques when anatomy or prior interventions demand a tailored solution.

Concurrently, systems-level changes-such as the expansion of ambulatory procedural settings and greater emphasis on value-based care-are reshaping where and how treatments are delivered. Partnerships between device manufacturers, clinical centers of excellence, and digital health innovators are accelerating iterative improvements in training, remote proctoring, and outcome monitoring. These cumulative shifts are redefining standard-of-care propositions and creating new opportunities for stakeholders who can align clinical evidence with operational readiness and procurement agility.

Assessment of how the 2025 United States tariff adjustments have reshaped supply chains, procurement practices, and clinical delivery pathways in aneurysm care

The tariff measures implemented in 2025 have introduced a complex overlay of trade policy considerations into the supply chains that support intracranial aneurysm care. Manufacturers that rely on cross-border sourcing for implants, specialized metals, and precision components have faced elevated input costs and extended lead times. In response, many suppliers have reevaluated sourcing footprints, prioritizing supplier diversification and contracts that mitigate single-source dependencies.

Hospital procurement teams and clinical service providers have felt the reverberations through higher acquisition prices for select devices and the need for more rigorous inventory management. These pressures have prompted a shift toward longer-term supplier agreements and increased interest in bundled purchasing arrangements to stabilize unit costs. Regulatory compliance and customs-related administrative burdens have also contributed to slower replenishment cycles, encouraging providers to hold larger safety stocks or to qualify alternative device options to avoid procedural interruptions.

At the strategic level, the tariff environment has accelerated conversations about nearshoring and regional manufacturing partnerships that can reduce exposure to tariff volatility. Device developers and distributors are exploring localized assembly and component sourcing to preserve competitiveness. In parallel, clinicians and hospital leaders are reassessing procurement frameworks to balance cost containment with clinical quality, emphasizing vendor partnerships that demonstrate reliability, local support, and clear post-market surveillance capabilities. These dynamics are reshaping commercial strategies and operational planning across the ecosystem.

Segment-driven insights explaining how treatment modalities, aneurysm locations, patient demographics, and clinical settings influence clinical pathways and adoption dynamics

Segment-level dynamics reveal differentiated adoption patterns and clinical considerations across treatment modalities, anatomical locations, patient demographics, and care settings. When analyzed by treatment type-Endovascular Coiling, Flow Diversion, and Surgical Clipping-each modality presents distinct strengths: coiling remains a mainstay for saccular lesions amenable to endovascular access; flow diversion has expanded options for wide-neck and fusiform aneurysms where vessel reconstruction is desirable; and surgical clipping retains importance for complex bifurcation anatomy and ruptured lesions where immediate mechanical exclusion is required.

Aneurysm location further nuances clinical decision making. Lesions arising in the anterior communicating artery, basilar artery, middle cerebral artery, and posterior communicating artery exhibit unique technical challenges and rupture risk profiles, influencing modality selection, adjunct device use, and anticipated perioperative courses. Patient age group segmentation also affects therapeutic strategy: adult patients commonly present with a wider array of comorbidities that influence antiplatelet planning and device choice, geriatric patients require careful balance between procedural benefit and frailty-related risk, and pediatric cases demand specialized devices and lifelong surveillance strategies that account for growth and long-term durability.

End users shape delivery models and resource allocation. Ambulatory Surgery Centers are increasingly relevant for select elective endovascular cases with predictable recovery trajectories, Diagnostic Centers play a pivotal role in early detection and noninvasive surveillance pathways, and Hospitals continue to be the primary site for complex interventions and acute rupture management due to their integrated critical care and neurosurgical capabilities. Taken together, these segmentation lenses inform clinical pathways, procurement priorities, and investment decisions across the continuum of care.

Regional perspectives on clinical adoption, infrastructure investment, and access pathways shaping intracranial aneurysm care across the Americas, EMEA, and Asia-Pacific

Regional variations in clinical practice, regulatory frameworks, and healthcare infrastructure drive differentiated approaches to intracranial aneurysm care across the major geographies. In the Americas, a concentration of specialized centers, integrated care pathways, and reimbursement models that increasingly reward procedural efficacy support rapid adoption of advanced endovascular techniques and ancillary technologies. Clinical networks and referral patterns in this region often facilitate centralization of high-complexity cases in tertiary centers while enabling ambulatory procedural growth for suitable elective cases.

In Europe, Middle East & Africa, heterogeneity is pronounced: Western European systems frequently combine strong clinical trial ecosystems with well-established neurointerventional programs, whereas segments of the Middle East and Africa are focused on building infrastructure, training local specialists, and improving access to diagnostic imaging. Regulatory harmonization efforts and regional procurement consortia influence device introduction timelines and pricing dynamics, prompting manufacturers to tailor market entry strategies accordingly.

The Asia-Pacific region demonstrates rapid capacity expansion, investment in tertiary neurovascular centers, and a strong emphasis on domestic device development in some countries. A high burden of undiagnosed cerebrovascular disease in certain populations has heightened focus on screening initiatives and diagnostic center expansion. Across all regions, cross-border collaborations, clinical training exchanges, and remote proctoring are increasingly important mechanisms for transferring technique and technology, thereby reducing variability in outcomes and accelerating uptake of evidence-based approaches.

Company-level analysis highlighting how established manufacturers, focused innovators, and service partnerships are reshaping device portfolios and clinical adoption trajectories

Company-level dynamics reflect a blend of entrenched manufacturers, agile specialist firms, and new entrants pushing on innovative device platforms and digital adjuncts. Established medical device companies continue to leverage global distribution channels, regulatory experience, and extensive clinical evidence to support broad clinical adoption of staple technologies. At the same time, specialized firms and startups concentrate on differentiated technical advantages-such as novel flow modulation architectures, bioactive coatings that promote endothelialization, and next-generation delivery systems that prioritize navigability in tortuous anatomy.

Collaborations between device developers and digital health providers are becoming more prevalent, with partnerships focused on advanced imaging analytics, computational fluid modeling, and post-market outcome tracking. These arrangements help demonstrate comparative performance, support clinician training, and generate real-world evidence that can accelerate institutional adoption. In addition, service providers offering end-to-end training, remote proctoring, and device support are gaining prominence as hospitals and ambulatory centers seek to reduce learning curve barriers for complex interventions.

Across the competitive landscape, successful firms combine technical differentiation with robust clinical data, proactive regulatory engagement, and local support capabilities. Companies that invest in clinician education, evidence generation, and supply chain resilience are better positioned to navigate procurement scrutiny and to sustain uptake within high-volume centers as well as emerging treatment sites.

Practical strategic recommendations for device developers, providers, and payers to accelerate innovation adoption, enhance resilience, and improve patient-centered aneurysm care

Industry leaders should prioritize a set of strategic actions to capitalize on clinical innovation while addressing operational and policy constraints. First, aligning product development with clinician-validated use cases and real-world evidence programs will reduce adoption friction and generate compelling value propositions for procurement committees. Close collaboration with high-volume clinical centers for investigator-initiated studies, registries, and training programs can create durable credibility and accelerate dissemination of best practices.

Second, strengthening supply chain resilience is essential. Leaders should diversify sourcing, evaluate regional assembly or nearshoring opportunities, and establish flexible contracting arrangements that include contingency inventory and transparent lead-time commitments. These steps reduce exposure to tariff-driven cost shocks and enhance the ability to support procedural continuity at provider sites.

Third, investing in training and service models that lower procedural learning curves will facilitate broader adoption across hospitals and ambulatory settings. Remote proctoring, modular training curricula, and outcome-driven support models can increase clinician confidence and reduce procedural variability. Fourth, engaging proactively with payers and health systems to articulate cost-effectiveness narratives grounded in clinical outcomes and patient-centered metrics will help align reimbursement pathways with innovation adoption. Finally, leaders should pursue interoperable digital strategies that integrate imaging analytics, outcome registries, and patient-reported outcomes to demonstrate long-term value and support continuous improvement.

Transparent research methodology describing integrated clinical, commercial, and supply chain analyses used to validate insights and support strategic recommendations

The research synthesis draws on a multi-modal methodology that integrates clinical literature review, expert interviews, device labeling and regulatory documentation, and supply chain analyses to assemble a holistic view of intracranial aneurysm care dynamics. Primary qualitative inputs include structured interviews with interventional neuroradiologists, neurosurgeons, procurement leaders, and device design engineers to surface real-world constraints, technology performance considerations, and adoption drivers. These perspectives were triangulated with peer-reviewed clinical studies, procedural guidelines, and public regulatory filings to ensure technical accuracy and clinical relevance.

Supply chain and policy analyses relied on trade data, procurement case studies, and publicly available tariff schedules to assess how recent policy shifts influence device availability and lead times. Where appropriate, the methodology incorporated scenario-based impact assessments to explore potential operational responses to supply disruptions, without producing deterministic forecasts. Data validation steps included cross-referencing expert feedback with documentary evidence, and iterative review cycles to reconcile divergent views and ensure robustness of insights.

The result is a framework that emphasizes clinical, commercial, and operational lenses and that supports actionable recommendations tailored to diverse stakeholders, from device innovators and hospital procurement teams to clinician educators and policy advisors.

Concise conclusion that integrates clinical progress, systemic challenges, and strategic priorities for stakeholders committed to improving aneurysm outcomes and access

This analysis synthesizes clinical innovation, supply chain evolution, and strategic implications to present a cohesive view of current intracranial aneurysm care dynamics. Advances in device technology and imaging have materially expanded therapeutic options, while system-level forces-such as procurement pressures and trade policy shifts-have introduced new operational considerations that affect adoption and access. The intersection of these trends underscores the importance of aligning clinical evidence generation with resilient commercial strategies and targeted clinician support.

Stakeholders who coordinate across clinical, regulatory, and supply chain domains will be best positioned to accelerate durable adoption of beneficial technologies while mitigating disruption. Emphasizing outcomes, investing in clinician training, and pursuing regionally informed supply chain strategies will help institutions maintain procedural continuity and optimize patient outcomes. In sum, the path forward requires integrated planning that balances innovation uptake with pragmatic operational controls, thereby ensuring that clinical advances translate into tangible improvements in patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Intracranial Aneurysm Market, by Treatment Type

  • 8.1. Endovascular Coiling
  • 8.2. Flow Diversion
  • 8.3. Surgical Clipping

9. Intracranial Aneurysm Market, by Aneurysm Location

  • 9.1. Anterior Communicating Artery
  • 9.2. Basilar Artery
  • 9.3. Middle Cerebral Artery
  • 9.4. Posterior Communicating Artery

10. Intracranial Aneurysm Market, by Patient Age Group

  • 10.1. Adult
  • 10.2. Geriatric
  • 10.3. Pediatric

11. Intracranial Aneurysm Market, by End Users

  • 11.1. Ambulatory Surgery Centers
  • 11.2. Diagnostic Centers
  • 11.3. Hospitals

12. Intracranial Aneurysm Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Intracranial Aneurysm Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Intracranial Aneurysm Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Intracranial Aneurysm Market

16. China Intracranial Aneurysm Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Acandis GmbH
  • 17.6. B. Braun Melsungen AG
  • 17.7. Boston Scientific Corporation
  • 17.8. Cook Group Inc
  • 17.9. Delta Surgical
  • 17.10. Evasc Neurovascular Enterprises ULC
  • 17.11. InspireMD Inc
  • 17.12. Integer Holdings Corporation
  • 17.13. Integra LifeSciences
  • 17.14. Johnson & Johnson
  • 17.15. Kaneka Corporation
  • 17.16. Medtronic plc
  • 17.17. Merit Medical Systems Inc
  • 17.18. MicroPort Scientific Corporation
  • 17.19. Penumbra Inc
  • 17.20. Phenox GmbH
  • 17.21. Rapid Medical
  • 17.22. Raumedic AG
  • 17.23. Shape Memory Medical
  • 17.24. Stryker Corporation
  • 17.25. Terumo Corporation
  • 17.26. Wallaby Medical

LIST OF FIGURES

  • FIGURE 1. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INTRACRANIAL ANEURYSM MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INTRACRANIAL ANEURYSM MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY ANEURYSM LOCATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY END USERS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES INTRACRANIAL ANEURYSM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA INTRACRANIAL ANEURYSM MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY ENDOVASCULAR COILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY ENDOVASCULAR COILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY ENDOVASCULAR COILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY FLOW DIVERSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY FLOW DIVERSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY FLOW DIVERSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY SURGICAL CLIPPING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY SURGICAL CLIPPING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY SURGICAL CLIPPING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY ANEURYSM LOCATION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY ANTERIOR COMMUNICATING ARTERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY ANTERIOR COMMUNICATING ARTERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY ANTERIOR COMMUNICATING ARTERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY BASILAR ARTERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY BASILAR ARTERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY BASILAR ARTERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY MIDDLE CEREBRAL ARTERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY MIDDLE CEREBRAL ARTERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY MIDDLE CEREBRAL ARTERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY POSTERIOR COMMUNICATING ARTERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY POSTERIOR COMMUNICATING ARTERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY POSTERIOR COMMUNICATING ARTERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS INTRACRANIAL ANEURYSM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS INTRACRANIAL ANEURYSM MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS INTRACRANIAL ANEURYSM MARKET SIZE, BY ANEURYSM LOCATION, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS INTRACRANIAL ANEURYSM MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS INTRACRANIAL ANEURYSM MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA INTRACRANIAL ANEURYSM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA INTRACRANIAL ANEURYSM MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA INTRACRANIAL ANEURYSM MARKET SIZE, BY ANEURYSM LOCATION, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA INTRACRANIAL ANEURYSM MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA INTRACRANIAL ANEURYSM MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA INTRACRANIAL ANEURYSM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA INTRACRANIAL ANEURYSM MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. LATIN AMERICA INTRACRANIAL ANEURYSM MARKET SIZE, BY ANEURYSM LOCATION, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA INTRACRANIAL ANEURYSM MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA INTRACRANIAL ANEURYSM MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL ANEURYSM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL ANEURYSM MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL ANEURYSM MARKET SIZE, BY ANEURYSM LOCATION, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL ANEURYSM MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL ANEURYSM MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE INTRACRANIAL ANEURYSM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE INTRACRANIAL ANEURYSM MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE INTRACRANIAL ANEURYSM MARKET SIZE, BY ANEURYSM LOCATION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE INTRACRANIAL ANEURYSM MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE INTRACRANIAL ANEURYSM MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 71. MIDDLE EAST INTRACRANIAL ANEURYSM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. MIDDLE EAST INTRACRANIAL ANEURYSM MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. MIDDLE EAST INTRACRANIAL ANEURYSM MARKET SIZE, BY ANEURYSM LOCATION, 2018-2032 (USD MILLION)
  • TABLE 74. MIDDLE EAST INTRACRANIAL ANEURYSM MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. MIDDLE EAST INTRACRANIAL ANEURYSM MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 76. AFRICA INTRACRANIAL ANEURYSM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. AFRICA INTRACRANIAL ANEURYSM MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. AFRICA INTRACRANIAL ANEURYSM MARKET SIZE, BY ANEURYSM LOCATION, 2018-2032 (USD MILLION)
  • TABLE 79. AFRICA INTRACRANIAL ANEURYSM MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. AFRICA INTRACRANIAL ANEURYSM MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC INTRACRANIAL ANEURYSM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC INTRACRANIAL ANEURYSM MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC INTRACRANIAL ANEURYSM MARKET SIZE, BY ANEURYSM LOCATION, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC INTRACRANIAL ANEURYSM MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC INTRACRANIAL ANEURYSM MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. ASEAN INTRACRANIAL ANEURYSM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. ASEAN INTRACRANIAL ANEURYSM MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. ASEAN INTRACRANIAL ANEURYSM MARKET SIZE, BY ANEURYSM LOCATION, 2018-2032 (USD MILLION)
  • TABLE 90. ASEAN INTRACRANIAL ANEURYSM MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. ASEAN INTRACRANIAL ANEURYSM MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 92. GCC INTRACRANIAL ANEURYSM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GCC INTRACRANIAL ANEURYSM MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. GCC INTRACRANIAL ANEURYSM MARKET SIZE, BY ANEURYSM LOCATION, 2018-2032 (USD MILLION)
  • TABLE 95. GCC INTRACRANIAL ANEURYSM MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GCC INTRACRANIAL ANEURYSM MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPEAN UNION INTRACRANIAL ANEURYSM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPEAN UNION INTRACRANIAL ANEURYSM MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPEAN UNION INTRACRANIAL ANEURYSM MARKET SIZE, BY ANEURYSM LOCATION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPEAN UNION INTRACRANIAL ANEURYSM MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPEAN UNION INTRACRANIAL ANEURYSM MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 102. BRICS INTRACRANIAL ANEURYSM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. BRICS INTRACRANIAL ANEURYSM MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. BRICS INTRACRANIAL ANEURYSM MARKET SIZE, BY ANEURYSM LOCATION, 2018-2032 (USD MILLION)
  • TABLE 105. BRICS INTRACRANIAL ANEURYSM MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. BRICS INTRACRANIAL ANEURYSM MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 107. G7 INTRACRANIAL ANEURYSM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. G7 INTRACRANIAL ANEURYSM MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. G7 INTRACRANIAL ANEURYSM MARKET SIZE, BY ANEURYSM LOCATION, 2018-2032 (USD MILLION)
  • TABLE 110. G7 INTRACRANIAL ANEURYSM MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. G7 INTRACRANIAL ANEURYSM MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 112. NATO INTRACRANIAL ANEURYSM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. NATO INTRACRANIAL ANEURYSM MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. NATO INTRACRANIAL ANEURYSM MARKET SIZE, BY ANEURYSM LOCATION, 2018-2032 (USD MILLION)
  • TABLE 115. NATO INTRACRANIAL ANEURYSM MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. NATO INTRACRANIAL ANEURYSM MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL INTRACRANIAL ANEURYSM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. UNITED STATES INTRACRANIAL ANEURYSM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 119. UNITED STATES INTRACRANIAL ANEURYSM MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. UNITED STATES INTRACRANIAL ANEURYSM MARKET SIZE, BY ANEURYSM LOCATION, 2018-2032 (USD MILLION)
  • TABLE 121. UNITED STATES INTRACRANIAL ANEURYSM MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. UNITED STATES INTRACRANIAL ANEURYSM MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 123. CHINA INTRACRANIAL ANEURYSM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 124. CHINA INTRACRANIAL ANEURYSM MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. CHINA INTRACRANIAL ANEURYSM MARKET SIZE, BY ANEURYSM LOCATION, 2018-2032 (USD MILLION)
  • TABLE 126. CHINA INTRACRANIAL ANEURYSM MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. CHINA INTRACRANIAL ANEURYSM MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)